| The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study L Delgado-Ortega, A González-Domínguez, JM Borrás, J Oliva-Moreno, ... The European Journal of Health Economics 20, 135-147, 2019 | 21 | 2019 |
| Cost–utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain C Moya-Alarcón, A González-Domínguez, S Simon, I Pérez-Román, ... Clinical and Translational Oncology 21, 1076-1084, 2019 | 10 | 2019 |
| Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain? C Moya-Alarcón, A González-Domínguez, Y Ivanova-Markova, ... Gynecologic Oncology 164 (2), 406-414, 2022 | 6 | 2022 |
| Societal and economic burden of migraine in Spain: results from the 2020 National Health and Wellness Survey D García-Azorín, C Moya-Alarcón, B Armada, M Sánchez del Río The Journal of Headache and Pain 25 (1), 38, 2024 | 2 | 2024 |
| Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients C Moya-Alarcon, G Piera, A Callejo, A Gasco Journal of Comparative Effectiveness Research 11 (1), 13-27, 2021 | 1 | 2021 |
| Migraine treatment: quo vadis? Real-world data study (2015–2022) in Spain M Carmo, A Muñiz, B Armada, C Moya-Alarcón, J Pascual Gómez, ... BMC, 2024 | | 2024 |
| Migraine treatment: quo vadis? Real-world data study (2015–2022) in Spain P Pozo-Rosich, M Carmo, A Muñiz, B Armada, C Moya-Alarcón, J Pascual BMC neurology 24 (1), 107, 2024 | | 2024 |
| Economic impact of managing invasive mold disease with isavuconazole compared with liposomal amphotericin B followed by posaconazole in Spain C Moya-Alarcón, JR Azanza, J Barberán, R Ferrer, M Kwon, A Moreno, ... Expert Review of Anti-infective Therapy, 1-8, 2024 | | 2024 |
| Olaparib cost effective for in BRCA-mutated advanced ovarian carcinoma in Spain C Moya-Alarcon PharmacoEconomics & Outcomes News 893, 16-11, 2021 | | 2021 |
| Economic Impact of Olaparib in Patients with Platinum Sensitive Relapsed Brca Mutated Epithelial Ovarian Cancer in Spain L Delgado-Ortega, C Moya-Alarcón, D Carcedo, A Villacampa, L Cordero Value in Health 19 (7), A718, 2016 | | 2016 |
| Ovarcost Study: Economic Burden of Epithelial Ovarian Cancer in Spain L Delgado-Ortega, C Moya-Alarcón, JM Borras, EG de la Haba, ... Value in Health 19 (7), A724, 2016 | | 2016 |
| Evaluación económica del test genético BRCA1/2 en mujeres con cáncer de ovario epitelial en España: análisis coste-utilidad AB Sánchez-Heras, E Bayo-Lozano, A González-Martín, C Moya-Alarcón, ... Ratio 20, 0-10.000, 0 | | |
